We are a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Our proprietary Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, approach is pioneering a new category of immunotherapies that combines the precision of antibody targeting with the immune system’s strength by activating and recruiting myeloid cells to reprogram the tumor and invoke an adaptive immune response.

Our lead product candidate BDC-1001 is a human epidermal growth factor receptor 2, or HER2, Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists, for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. This includes HER2+ breast cancer, HER2 low breast cancer, HER2+ gastric cancer and other HER2+ cancers. We initiated a Phase 1/2 trial of BDC-1001 in the first quarter of 2020 to treat patients with HER2-expressing solid tumors. We are in the dose escalation portion of the trial and expect to move into Phase 2 dose expansions in key solid tumor indications with unmet medical need in 2021. 

(Note: Bolt Biotherapeutics priced its upsized IPO on Feb. 4, 2021: 11.5 million shares at $20 each – up from its recently increased size of 10.5 million shares at $18 to19 in its S-1/A filing on Feb. 3 – to raise $230 million. The IPO’s initial terms were 8.83 million shares at a $16-to-$18 price range.)